On August 5, Twist Bioscience Corp rose 5.45% in pre-market trading, trading at $104.86/share, with turnover of $962,000.

On the news front, the company previously reported fiscal Q3 results with revenue of $118.4 million, up 23.2% year-over-year and beating the analyst consensus estimate of $114.5 million. More notably, the company raised its full-year revenue guidance to $456 million to $457 million and projected Q4 revenue of $123 million to $124 million, significantly above the FactSet consensus estimate of $117.4 million. While the quarterly EPS loss of $0.56 missed market expectations of a $0.51 loss and marked a reversal from the $0.33 per share profit in the year-ago period, the strong top-line momentum and above-consensus forward guidance continued to bolster investor confidence in the company's business expansion trajectory, driving the pre-market rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)